FLGT

#2872
Fulgent Genetics, Inc. - Common Stock
19.5 3 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
19.29
19.61
Jahresspanne
13.46
31.04
Tagesänderung
+0.83%
Monatliche Änderung
+17.58%
6 month change
+31.25%
Jahresänderung
-17.35%
Vorheriger Schlusskurs
19.3 7
Open
19.2 9
Tief
19.2 9
Hoch
19.6 1
Volumen
47
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Fulgent Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Fulgent Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Fulgent Genetics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Fulgent Genetics, Inc. annual report, FY2025
10-K

Fulgent Genetics, Inc. current report, Q4 FY2022

Full document

Fulgent Genetics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Fulgent Genetics, Inc. (FLGT) on November 7, 2022. The filing serves to disclose the company's financial results for the fiscal quarter ended September 30, 2022, and to announce a significant corporate acquisition.

Key Financial Metrics

The filing text references the announcement of financial results for the quarter ended September 30, 2022, but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the press release furnished as Exhibit 99.1, which is not included in the provided text.

Material Changes and Corporate Actions

  • Acquisition Announcement: On November 7, 2022, the Company announced the acquisition of Fulgent Pharma Holdings, Inc. This is a material change to the company's business structure and strategic direction.
  • Financial Results: The Company reported its Q3 2022 financial results, though specific performance metrics are not detailed in this summary document.

Guidance, Outlook, and Management Commentary

Management updated its investor presentation on November 7, 2022, to reflect the acquisition of Fulgent Pharma Holdings, Inc. and to provide business updates. The filing notes that the information regarding results and the acquisition is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act. No specific forward-looking guidance or risk factors are detailed within the text of this 8-K form itself.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific Q3 2022 revenue, net income, and cash flow figures.
  • Examine Exhibit 99.2 and 99.4 for details on the acquisition of Fulgent Pharma Holdings, Inc., including transaction terms and strategic rationale.
  • Verify the updated investor presentation (Exhibit 99.3) for any revised operational outlook or guidance.
  • Confirm the impact of the acquisition on the company's balance sheet and future liquidity position.

Nachrichten